Table 3 Changes in QTc interval during the surgery
Number of patients (%) | ||||
|---|---|---|---|---|
Ramosetron (n = 51) | Placebo (n = 52) | Risk difference (95 % CI) | P value | |
QTc interval prolongation > 500 ms | 1 (2.0 %) | 0 (0.0 %) | 2.0 % (−1.8 to 5.8) | 0.495 |
QTc interval increase > 60 ms | 5 (9.8 %) | 0 (0.0 %) | 9.8 % (1.6 to 18.0) | 0.021 |
QTc interval increase > 30 ms | 13 (25.5 %) | 12 (23.1 %) | 2.4 % (−14.2 to 19.0) | 0.775 |
Mean (SD) | Mean difference (95 % CI) | |||
Baseline QTc interval before injection (ms) | 395.1 ± 19.7 | 397.2 ± 19.8 | −2.09 (−9.85 to 5.66) | 0.593 |
Maximal change in QTc interval (ms) | 25.1 ± 22.0 | 17.5 ± 14.5 | 7.56 (0.34 to 14.78) | 0.040 |
QTc interval at postoperative day 1 (ms) | 428.9 ± 59.0 | 437.9 ± 56.3 | −9.02 (−33.32 to 15.28) | 0.463 |